文献速递膀胱癌与上尿路尿路上皮癌

口服二甲双胍治疗非肌层浸润性膀胱癌的II期标记病灶研究

A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2025-05-22

这项II期开放标签多中心标记病灶试验评估口服二甲双胍对非肌层浸润性膀胱癌标记病灶的作用,11例低级别Ta-T1患者接受二甲双胍每日至3000mg治疗3个月。仅1例完全缓解、1例部分缓解,9例病灶持续存在,其中5例出现新发Ta低级别病灶;常见不良事件为≤2级腹泻,未发现明确抗肿瘤证据。

要点

  • 口服二甲双胍3个月在11例NMIBC标记病灶中仅见1例完全缓解和1例部分缓解。
  • 9例标记病灶持续存在,其中5例出现新发Ta低级别病灶。
  • 最常见不良事件为≤2级腹泻,见于9/11例,无治疗相关严重不良事件。

核心结论

  • 未发现二甲双胍对膀胱癌具有抗肿瘤作用的决定性证据。

研究设计与样本

  • II期、开放标签、多中心标记病灶试验,纳入原发或复发、多发、低级别Ta-T1 NMIBC患者。
  • 经尿道电切组织学确认后保留一个肿瘤作为标记病灶,11例患者接受口服二甲双胍每日至3000mg治疗3个月。

主要发现

  • 观察到1例完全缓解和1例部分缓解。
  • 其余9例标记病灶持续存在,其中5例还出现新发Ta低级别病灶。
  • 最常见不良事件为≤2级腹泻,见于9/11例;无研究治疗相关严重不良事件。
  • 尿中二甲双胍浓度显著高于血中浓度。
  • 治疗前后免疫组化分析显示与二甲双胍作用机制相关标志物的表达无差异。

临床怎么用

  • 结果不支持口服二甲双胍用于NMIBC的膀胱内治疗目的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of metformin on non-muscle-invasive bladder cancer (NMIBC) marker lesions. PATIENTS AND METHODS: A phase II, open-label, multicentre, marker lesion trial using oral metformin in patients with primary or recurrent, multiple, low-grade Ta-T1 NMIBC was conducted. After transurethral resection for histological confirmation, leaving one tumour as a marker lesion, 11 patients were treated with oral metformin up to 3000 mg per day for 3 months. Reported outcomes included response of the marker lesion, safety of metformin, quality of life and pharmacological and immunohistochemical examinations of the mechanism of action of metformin. RESULTS: One complete response and one partial response were observed. In the other nine patients, the marker lesion remained, while five of these patients also developed new Ta low-grade lesions. Diarrhoea grade ≤ 2 was the most common adverse event (AE), observed in nine out of 11 patients. No serious AEs related to study treatment occurred. Metformin concentrations in the urine were significantly higher than metformin levels in the blood. Immunohistochemical analysis before and after treatment showed no difference in expression of markers associated with the mechanism of metformin. CONCLUSION: We did not find conclusive evidence for the hypothesis of an antitumour effect of metformin in bladder cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. van Hattum JW, Remmelink MJ, Nuijens ST, et al. A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 40404168. doi:10.1111/bju.16767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。